Q2 2026 Vaxart Inc Earnings Call Transcript
Key Points
- Positive 12-month safety data from the sentinel cohort showed zero vaccine-related serious adverse events and a favorable side-effect profile compared to mRNA vaccines.
- The oral pill vaccine demonstrated similar efficacy to an approved mRNA vaccine in the sentinel cohort, with comparable COVID-19 case rates.
- BARDA contract modification released $29 million in additional funding for expanded analysis, including mucosal immunity and subvariant sequencing.
- The main cohort of approximately 5,000 participants is fully enrolled, with top-line efficacy and safety data expected in the first half of 2027.
- The company has a $25 million share purchase agreement with Lincoln Park Capital, providing flexible access to capital with favorable terms.
- Management is actively pursuing non-dilutive funding options, including government grants and partnerships, to extend cash runway.
- Governance enhancements, including new board committees and a cooperation agreement with shareholders, strengthen oversight and alignment.
- Cash runway is only projected into the second quarter of 2027, which may not be sufficient to reach the Sanofi opt-in decision or other milestones.
- The norovirus program lacks secured funding, and its timeline is contingent on finding a partner or non-dilutive funding, creating uncertainty.
- BARDA retains final approval over the timing and content of all data readouts, which could delay releases and limit transparency.
- The sentinel cohort was not powered for efficacy, so the similar infection rates with mRNA vaccines are not statistically conclusive.
- Moderna's norovirus trial extension and HilleVax's failure may make potential partners more cautious, potentially complicating partnership discussions.
- The company had to lay off employees last year to reduce costs, reflecting financial strain and tough operational choices.
- The delay in releasing sentinel cohort data was attributed to BARDA protocols, indicating potential for similar delays with the main cohort.
Greetings, and welcome to the Vaxart Stockholder fireside chat.
(Operator Instructions)
As a reminder, this conference is being recorded. I would now like to turn the webcast over to David Carey of Finn Partners.
Joining us from Vaxart are Steve Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James F. Cummings, Chief Medical Officer; Jeroen Grasman, Chief Financial Officer; and Ed Berg, Senior Vice President and General Counsel.
Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, any partnerships with third-parties, timing of any anticipated regulatory approvals or that any such approval will be obtained, the company's future cash runway, ability to raise capital, and its product development and regulatory progress, including statements about its ongoing or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
